


HYDROGEN SULFIDE (H₂S) AND NEURODEGENERATIVE DISEASES

*From Molecular Mechanisms
to Neuroprotection*



Constantin Munteanu, PhD



Grigore T. Popa University of Medicine and Pharmacy Iași



Bagdasar-Arseni Emergency Clinical Hospital Bucharest



Romanian Association of Balneology



**NEURO
CONCLAVE 2026**

NEUROLOGY AND
NEUROLOGICAL DISORDERS




NEURO CONCLAVE 2026 • SINGAPORE



FROM TOXIC GAS TO NEUROPROTECTIVE MOLECULE

The remarkable evolution of hydrogen sulfide (H₂S)



From a hazardous gas to a vital signal – **H₂S is a key player in health and disease.**

Balneo and PRM Research Journal

Hydrogen sulfide (H₂S) - therapeutic relevance in rehabilitation and balneotherapy
Systematic literature review and meta-analysis based on the PRISMA paradigm

MUNTEANU Constantina^{1,2,3}, MUNTEANU Diana^{4,5}, ONOSE Gelu^{1,4}

Editor: Mihail HOTETETI, Romanian Association of Balneology, hoteteti@yahoo.com

Corresponding author: **Constantin MUNTEANU**, E-mail: office@bioclima.ro

1. Romanian Association of Balneology, Bucharest, Romania
2. Teaching Emergency Hospital "Bagdasar-Arseni", Bucharest, Romania
3. Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa", Iasi, Romania
4. Faculty of Medicine, Department of Physical and Rehabilitation Medicine, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
5. National Institute of Rehabilitation, Physical Medicine and Balneoclimatology, Bucharest, Romania

Abstract

Background. An active molecule in sulfurous mineral - medicinal waters and also in superepic mud is H₂S, a homeostatic gasotransmitter molecule that can actively penetrate the skin. While high levels of H₂S are extremely toxic, low levels are tolerated and have potential cytoprotective effects, with anti-inflammatory and antioxidant applications.

Objective. This systematic review aims to rigorously select related articles and identify within their content the main possible uses of hydrogen sulfide from balneary sources and to explain its physiological mechanisms and therapeutic properties.

Methods. To elaborate our systematic review, we have searched for relevant open access articles in 6 international databases: Cochrane, Elsevier, NCBI/PubMed, NCBIPMC, PEDro, and ISI Web of Knowledge/Science, published from January 2016 until July 2021. The contextually quoted keywords combinations/ synonyms used are specified on this page. The eligible articles were analyzed in detail regarding pathologies addressed by hydrogen sulfide. All articles with any design (reviews, randomized controlled trials, non-randomized controlled trials, case-control studies, cross-sectional studies), if eligible according to the above-mentioned selection methodology, containing in the title the selected combinations, were included in the analysis. Articles were excluded in the second phase if they did not reach the relevance criterion.

Results. Our search identified, first, 291 articles. After eliminating the duplicates and non-ISI articles, remained 121 papers. In the second phase, we applied a PEDro selection filter, resulting in 108 articles that passed the relevance criterion and were included in this systematic review.

Conclusions. H₂S biology and medical relevance are not fully understood and used adequately for sanogenic or medical purposes. More research is needed to fully understand the mechanisms and importance of this therapeutic gas. The link between balneotherapy and medical rehabilitation regarding the usage of hydrogen sulfide emphasizes the unity for this medical specialty.

Keywords: Hydrogen sulfide / H₂S AND balneotherapy / inhalations / mud / Rheumatoid arthritis / neuroprotection / neurodegenerative disorders / Stroke / Parkinson / Alzheimer / Huntington / vascular dementia / Immune system / Diabetes / Cancer / Cardiorespiration / Asthma / Allergic Rhinitis / COPD / COVID-19 / Burns / Analgesic effect / Clinical trials

176

	H ₂ S	NO	H ₂ O ₂	CO
Name	Hydrogen sulfide	Nitric oxide	Hydrogen peroxide	Carbon monoxide
Chemical formula	H-S-H	N=O	HO-OH	C=O
Molecular mass (g mol ⁻¹)	34.08	30.01	34.01	28.01
Chemical reactivity	Very high	Very high	High	Moderate
Toxicity concentration	5-30 µM	0.5-150 µM	0.5-500 µM	30-50 ppm
Enzymatic production	Animals: CBS, CSE, 3-MTS Plants: L-D-DES, CAS, CS, SiR	Animals: eNOS, iNOS, nNOS Plants: NRs, NOS?	Animals: SOD, POX Plants: PAO, SOD, POX	Animals: HO-1 Plants: HO-1
Concentration in cells	nM-µM	nM	nM-µM	nM-µM
Half life in vivo	Seconds-minutes	seconds	Seconds-minutes	Minutes
Protein modification	Persulfidation	s-nitrosation	s-sulfenylation	?

CBS: cystathionine β-synthase; CSE: Cystathionine γ-lyase; 3-MTS: 3-mercaptopyruvate sulfur transferase; L-D-DES: cysteine desulfhydrase; CAS: β-cyano-L-alanine synthase; CS: cysteine synthase; SiR: Sulfite reductase; NOS: Nitric oxide synthase; NRs: Nitrate reductases; PAO: polyamine oxidase; SOD: Superoxide dismutase; POX: peroxidase; HO-1: Heme oxygenase 1.


- Hydrogen sulfide (H₂S) - primarily a toxic gas, recognizable by its characteristic odor – (environmental / occupational hazard).
- H₂S - endogenous signaling molecule, comparable to nitric oxide and carbon monoxide.
- H₂S - gasotransmitter involved in vascular regulation, redox homeostasis, mitochondrial function, inflammation, cytoprotection, neuromodulation, and cellular adaptation.

WHY NEURODEGENERATION?

Common Mechanisms Underlying Neurodegenerative Diseases

1 OXIDATIVE STRESS

Excess reactive oxygen and nitrogen species damage proteins, lipids, and DNA.



3 NEUROINFLAMMATION

Activated microglia and chronic inflammation release cytokines that promote neuronal damage and synaptic loss.



2 MITOCHONDRIAL DYSFUNCTION

Impaired energy production, increased ROS, and defective mitophagy lead to neuronal injury.



4 PROTEIN AGGREGATION

Misfolded proteins such as A β , tau, α -synuclein, and TDP-43 aggregate, disrupting cellular function and connectivity.




These interconnected mechanisms converge to cause neuronal dysfunction and progressive cognitive decline.

Neurodegenerative diseases share several common mechanisms. Oxidative stress, mitochondrial dysfunction, chronic neuroinflammation, and protein aggregation progressively damage neurons and synaptic networks. H₂S intersects with all of these pathways. This is why it has attracted increasing attention as a systems-level regulator rather than as a single-target therapeutic molecule.

Abstract: Hydrogen sulfide (H₂S), a gas traditionally considered toxic, is now recognized as a vital endogenous signaling molecule with a complex physiology. This comprehensive review encompasses a systematic literature review that explores the intricate mechanisms underlying H₂S-induced vasodilation. The vasodilatory effects of H₂S are primarily mediated by activating ATP-sensitive potassium (K_{ATP}) channels, leading to membrane hyperpolarization and subsequent relaxation of vascular smooth muscle cells (VSMCs). Additionally, H₂S inhibits L-type calcium channels, reducing calcium influx and diminishing VSMC contraction. Beyond ion channel modulation, H₂S profoundly impacts cyclic nucleotide signaling pathways. It stimulates soluble guanylyl cyclase (sGC), increasing the production of cyclic guanosine monophosphate (cGMP). Elevated cGMP levels activate protein kinase G (PKG), which phosphorylates downstream targets like vasodilator-stimulated phosphoprotein (VASP) and promotes smooth muscle relaxation. The synergy between H₂S and nitric oxide (NO) signaling further amplifies vasodilation. H₂S enhances NO bioavailability by inhibiting its degradation and stimulating endothelial nitric oxide synthase (eNOS) activity, increasing cAMP levels and potent vasodilatory responses. Protein sulphylation, a post-translational modification, plays a crucial role in cell signaling. H₂S-S-sulfurates oxidized cysteine residues, while polysulfides (H₂S)_n are responsible for S-sulfurating reduced cysteine residues. Sulphylation of key proteins like K_{ATP} channels and sGC enhances their activity, contributing to the overall vasodilatory effect. Furthermore, H₂S interaction with endothelium-derived hyperpolarizing factor (EDHF) pathways adds another layer to its vasodilatory mechanism. By enhancing EDHF activity, H₂S facilitates the hyperpolarization and relaxation of VSMCs through gap junctions between endothelial cells and VSMCs. Recent findings suggest that H₂S can also modulate transient receptor potential (TRP) channels, particularly TRPV4 channels, in endothelial cells. Activating these channels by H₂S promotes calcium entry, stimulating the production of vasodilatory agents like NO and prostacyclin, thereby regulating vascular tone. The comprehensive understanding of H₂S-induced vasodilation mechanisms highlights its therapeutic potential. The multifaceted approach of H₂S in modulating vascular tone presents a promising strategy for developing novel treatments for hypertension, ischemic conditions, and other vascular disorders. The interaction of H₂S with ion channels, cyclic nucleotide signaling, NO pathways, ROS (Reactive Oxygen Species) scavenging, protein sulphylation, and EDHF underscores its complexity and therapeutic relevance. In conclusion, the intricate signaling paradigms of H₂S-induced vasodilation offer valuable insights into its physiological role and therapeutic potential, promising innovative approaches for managing various vascular diseases through the modulation of vascular tone.

Keywords: hydrogen sulfide (H₂S); vasodilation; protein sulphylation; ROS scavenging; endothelial function



ENDOGENOUS H_2S IN THE BRAIN

H_2S is synthesized in the brain by three major enzymes

- 1 CBS – Cystathionine β -Synthase**
Location: Neurons, astrocytes, vascular cells
Reaction: L-homocysteine + L-serine $\rightarrow$ cystathionine $\rightarrow$ cysteine $\rightarrow H_2S$
- 2 CSE – Cystathionine γ -Lyase**
Location: Neurons, astrocytes, microglia
Reaction: L-cysteine $\rightarrow$ pyruvate + NH_3 + H_2S
- 3 3-MST – 3-Mercaptopyruvate Sulfurtransferase**
Location: Mitochondria (highly expressed)
Reaction: 3-mercaptopyruvate + sulfane sulfur $\rightarrow$ pyruvate + H_2S

CBS
Mainly in neurons and astrocytes

H_2S is a naturally produced gasotransmitter in the brain, essential for neuroprotection, redox balance, and cellular homeostasis.

CSE
In neurons, astrocytes and microglia


3-MST
In mitochondria of neurons (main source of H_2S)

Physiological Roles of Brain-Derived H_2S




Endogenous H_2S production is essential for optimal brain function and protection against **neurodegenerative processes**.

H_2S is naturally produced in the central nervous system through the enzymes CBS, CSE, and 3-MST. These enzymatic systems are distributed among neurons, astrocytes, microglia, and mitochondria. Endogenous H_2S contributes to neurotransmission, neurovascular regulation, mitochondrial function, and antioxidant defense. Therefore, H_2S should be viewed as an integral component of normal brain physiology.



PILLAR 1: REDOX HOMEOSTASIS

H₂S Activates Nrf2 and Strengthens Antioxidant Defenses



H₂S-Nrf2 SIGNALING IS A CENTRAL PATHWAY FOR REDOX HOMEOSTASIS AND A FOUNDATION OF NEUROPROTECTION.

One of the most important functions of H₂S is the regulation of redox homeostasis. H₂S activates Nrf2-dependent signaling and promotes the expression of antioxidant enzymes such as HO-1, NQO1, SOD, catalase, and glutathione-related pathways. Through these mechanisms, H₂S may help limit oxidative damage and preserve neuronal survival under stressful conditions.

Abstract: Oxidative stress plays an essential role in neurodegenerative pathophysiology, acting as both a critical signaling mediator and a driver of neuronal damage. Hydrogen sulfide (H₂S), a versatile gasotransmitter, exhibits a similarly "Janus-faced" nature, acting as a potent antioxidant and cytoprotective molecule at physiological concentrations, but becoming detrimental when dysregulated. This review explores the dual roles of oxidative stress and H₂S in normal cellular physiology and pathophysiology, focusing on neurodegenerative disease progression. We highlight potential therapeutic opportunities for targeting redox and sulfur-based signaling systems in neurodegenerative diseases by elucidating the intricate balance between these opposing forces.

Keywords: oxidative stress; hydrogen sulfide (H₂S); neurodegenerative diseases; redox signaling; Janus face; neuroinflammation



Academic Editor: Marco Fiume

Received: 27 February 2025

Revised: 9 March 2025

Accepted: 17 March 2025


Published: 19 March 2025

Citation: Munteanu, C.; Galaction, A.I.; Onose, G.; Turnea, M.; Rotariu, M. The Janus Face of Oxidative Stress and Hydrogen Sulfide: Insights into Neurodegenerative Disease Pathogenesis. *Antioxidants* 2025, 14, 360. <https://doi.org/10.3390/ant14030360>

1. Introduction

Neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), are a growing medical challenge worldwide [1–3]. These conditions are typically characterized by progressive neuronal loss, accumulation of misfolded or aggregated proteins, peroxisomal dysfunction [4,5], and persistent neuroinflammation [6–10]. While each disorder has distinct clinical features—ranging from cognitive decline to motor dysfunction, there is an overarching theme that oxidative stress contributes significantly to the pathological cascades involved [11–13]. Excessive ROS in the central nervous system (CNS) can damage neuronal membranes through lipid peroxidation, alter synaptic function, and potentially accelerate protein misfolding [14–17].

Concurrently, the inflammatory microenvironment within the brain can exacerbate



PILLAR 2: MITOCHONDRIAL DYSFUNCTION

H₂S Supports Mitochondrial Health and Energy Production

HOW H₂S SUPPORTS MITOCHONDRIA

ENHANCES ATP PRODUCTION

Optimizes electron transport chain efficiency.

MAINTAINS MEMBRANE POTENTIAL

Preserves mitochondrial integrity and function.

REDUCES OXIDATIVE STRESS

Directly scavenges ROS and boosts antioxidant defenses.

REGULATES MITOCHONDRIAL DYNAMICS

Promotes balanced fission and fusion for quality control.

PROMOTES MITOPHAGY

Facilitates removal of damaged mitochondria and cellular renewal.

IMPROVES ENERGY METABOLISM

Supports efficient glucose and fatty acid utilization.

OUTCOMES



Increased Energy Production



Enhanced Cellular Resilience



Protection Against Mitochondrial-Mediated Damage



Improved Neuronal Function and Survival



Support for Neurodegenerative Disease Prevention



By preserving mitochondrial function, H₂S ensures the energy and resilience neurons need to **survive and thrive**.



current issues in
molecular biology



Review

Topical Reappraisal of Molecular Pharmacological Approaches to Endothelial Dysfunction in Diabetes Mellitus Angiopathy

Constantin Munteanu ^{1,2,*}, Mariana Rotariu ¹, Marius-Alexandru Turnea ¹, Aurelian Anghelescu ^{2,3}, Irina Albadi ^{4,5}, Gabriela Dogaru ^{6,7}, Simziana Calina Silisteanu ⁸, Elena Valentina Ionescu ^{4,9}, Florentina Carmen Firan ¹⁰, Anca Mirela Ionescu ¹¹, Carmen Oprea ^{4,9} and Gelu Onose ^{2,11,*}

¹ Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa" Iasi, 70054 Iasi, Romania; mariana.rotariu@unfiasi.ro (M.R.); marius.turnea@unfiasi.ro (M.-A.T.)

² Neurovascular Rehabilitation Division, Teaching Emergency Hospital "Bagdasar-Areni", 01015 Bucharest, Romania; aurelian.anghelescu@unfiasi.ro

³ Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 02002 Bucharest, Romania

⁴ Faculty of Medicine, Ovidius University of Constanta, 90070 Constanta, Romania; irina.albadi@yahoo.com (I.A.); elena.ionescu@univ-ovidius.ro (E.V.I.); carmen.oprea@univ-ovidius.ro (C.O.)

⁵ Teaching Emergency County Hospital "Sf. Apostol Andrei", 90051 Constanta, Romania

⁶ Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania; gabriela.dogaru@unfcluj.ro

⁷ Clinical Rehabilitation Hospital, 400437 Cluj-Napoca, Romania

⁸ Faculty of Medicine, Biological Sciences, "Stefan cel Mare" University of Suceava, 720229 Suceava, Romania; simziana.silisteanu@unfiasi.ro

⁹ Baneasa and Rehabilitation Sanatorium of Teichigiol, 900100 Teichigiol, Romania

¹⁰ Teaching Emergency Hospital of the Ilfov County, 022113 Bucharest, Romania; firan.carmen@yahoo.com

¹¹ Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 02002 Bucharest, Romania; anca.ionescu@unfcluj.ro

* Correspondence: constantin.munteanu@unfiasi.ro (C.M.); gelu.onose@unfcluj.ro (G.O.)



Citation: Munteanu, C.; Rotariu, M.; Turnea, M.-A.; Anghelescu, A.; Albadi, I.; Dogaru, G.; Silisteanu, S.C.; Ionescu, E.V.; Firan, C.; Oprea, C.; Onose, G. Topical Reappraisal of Molecular Pharmacological Approaches to Endothelial Dysfunction in Diabetes Mellitus Angiopathy. *Current Issues in Molecular Biology* **2022**, *44*, 3378–3397. <https://doi.org/10.3390/cimb44080231>

Academic Editor: Tildaraj Thumani

Received: 16 June 2022

Accepted: 11 July 2022

Published: 28 July 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors.

Abstract: Diabetes mellitus (DM) is a frequent medical problem, affecting more than 4% of the population in most countries. In the context of diabetes, the vascular endothelium can play a crucial pathophysiological role. If a healthy endothelium—which is a dynamic endocrine organ with autocrine and paracrine activity—regulates vascular tone and permeability and assures a proper balance between coagulation and fibrinolysis, and vasodilation and vasoconstriction, then, in contrast, a dysfunctional endothelium has received increasing attention as a potential contributor to the pathogenesis of vascular disease in diabetes. Hyperglycemia is indicated to be the major causative factor in the development of endothelial dysfunction. Furthermore, many sheds of evidence suggest that the progression of insulin resistance in type 2 diabetes is parallel to the advancement of endothelial dysfunction in atherosclerosis. To present the state-of-the-art data regarding endothelial dysfunction in diabetic micro- and macroangiopathy, we constructed this literature review based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We interrogated five medical databases: Elsevier, PubMed, PMC, PEDro, and ISI Web of Science.

Keywords: diabetes mellitus; endothelial dysfunction; microangiopathy; macroangiopathy

Copyright: © 2022 by the authors.

MDPI

Current Issues in Molecular Biology

Volume 44, Issue 8, August 2022

Article

3378–3397

DOI: 10.3390/cimb44080231

Check for updates

View Full Article

Download Article

Download PDF

Download XML

Download Full Text

Download Figure

Download Table

Download Citation

Download References

Download Figures

Download Tables

Download Citations

Download References

Download Figures

Download Tables

Download Citations

Download References

Download Figures

Download Tables

Download Citations

Download References

Download Figures

Download Tables

Download Citations

Download References

Download Figures

Download Tables

Download Citations

Download References

Mitochondria are central targets of H₂S signaling. Physiological concentrations of H₂S may support electron transport, ATP production, mitophagy, and mitochondrial quality control. Since mitochondrial dysfunction is a hallmark of neurodegeneration, preserving mitochondrial resilience is one of the most attractive therapeutic aspects of H₂S biology.



PILLAR 3: NEUROINFLAMMATION CONTROL

H₂S MODULATES MICROGLIAL ACTIVATION AND SUPPRESSES NEUROINFLAMMATION




**NEURO
CONCLAVE 2026**

NEUROLOGY AND
NEUROLOGICAL DISORDERS


ACTIVATED MICROGLIA

Pro-inflammatory phenotype



INHIBITED MICROGLIA

Anti-inflammatory phenotype



H₂S SUPPRESSES NEUROINFLAMMATION AND PROTECTS THE BRAIN

Harnessing Gasotransmitters to Combat Age-Related Oxidative Stress in Smooth Muscle and Endothelial Cells

Constantin Munteanu ^{1,2,*}, Anca Irina Galaction ^{1,†}, Gelu Onose ^{2,3,†}, Marius Turnea ^{1,4,*} and Mariana Rotariu ¹

¹ Department of Biomedical Sciences, Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa", 700454 Iasi, Romania; anca.galaction@umfiasi.ro (A.I.G.); mariana.rotariu@umfiasi.ro (M.R.)

² Neuromuscular Rehabilitation Clinic Division, Clinical Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania; gelu.onose@umfiasi.ro


³ Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania

* Correspondence: constantin.munteanu@umfiasi.ro (C.M.); marius.turnea@umfiasi.ro (M.T.)

Abstract: Age-related oxidative stress is a critical factor in vascular dysfunction, contributing to hypertension and atherosclerosis. Smooth muscle cells and endothelial cells are particularly susceptible to oxidative damage, which exacerbates vascular aging through cellular senescence, chronic inflammation, and arterial stiffness. Gasotransmitters—hydrogen sulfide (H₂S), nitric oxide (NO), and carbon monoxide (CO)—are emerging as promising therapeutic agents for counteracting these processes. This review synthesizes findings from recent studies focusing on the mechanisms by which H₂S, NO, and CO influence vascular smooth muscle and endothelial cell function. Therapeutic strategies involving exogenous gasotransmitter delivery systems and combination therapies were analyzed. H₂S enhances mitochondrial bioenergetics, scavenges ROS, and activates antioxidant pathways. NO improves endothelial function, promotes vasodilation, and inhibits platelet aggregation. CO exhibits cytoprotective and anti-inflammatory effects by modulating heme oxygenase activity and ROS production. In preclinical studies, gasotransmitter-releasing molecules (e.g., NaHS, SNAP, CORMs) and targeted delivery systems show significant promise. Synergistic effects with lifestyle modifications and antioxidant therapies further enhance their therapeutic potential. In conclusion, gasotransmitters hold significant promise as therapeutic agents to combat age-related oxidative stress in vascular cells. Their multifaceted mechanisms and innovative delivery approaches make them potential candidates for treating vascular dysfunction and promoting healthy vascular aging. Further research is needed to translate these findings into clinical applications.

Keywords: gasotransmitters; oxidative stress; vascular aging; endothelial cells; smooth muscle cells; hydrogen sulfide; nitric oxide; carbon monoxide

1. Introduction




Neuroinflammation is increasingly recognized as a driver of neurodegenerative progression. H₂S may influence microglial activation and cytokine production, including TNF-α, IL-1β, and IL-6. Rather than completely suppressing inflammation, H₂S appears to modulate inflammatory responses and promote a more balanced neuroimmune environment.



PILLAR 4: PROTEIN HOMEOSTASIS

H₂S MAINTAINS PROTEIN HOMEOSTASIS AND PREVENTS TOXIC AGGREGATION

PROTEIN AGGREGATION CASCADE



KEY PATHOLOGICAL PROTEINS



H₂S PRESERVES PROTEIN HOMEOSTASIS AND PROTECTS THE BRAIN

**NEURO
CONCLAVE 2026**
NEUROLOGY AND
NEUROLOGICAL DISORDERS

Review

Recent Advances in Molecular Research on Hydrogen Sulfide (H₂S) Role in Diabetes Mellitus (DM)—A Systematic Review

Constantin Munteanu ^{1,2,*}, Mariana Rotariu ¹, Marius Turnea ¹, Gabriela Dogaru ^{3,4}, Cristina Popescu ¹, Aura Spina ^{2,5}, Ioana Andone ^{2,5}, Ruxandra Postoiu ², Elena Valentina Ionescu ^{6,7}, Carmen Oprea ^{6,7}, Irina Albadi ^{6,8} and Gelu Onose ^{2,5,*}

¹ Faculty of Medical Bioengineering, University of Medicine and Pharmacy “Grigore T. Popa” Iasi, 700115 Iasi, Romania; mariana.rotariu@unimib.ro (M.R.); munteanumarian@unimib.ro (C.M.); ² Teaching Emergency Hospital “Bagdasar-Arseni”, 06003 Bucharest, Romania; cristina.popescu@ecg-hospital.ro (C.P.); astra.spina@unimib.ro (A.S.); ioana.andone@unimib.ro (I.A.); ³ Postdoctoral Researcher, 06003 Bucharest, Romania; gabriela.dogaru@unimib.ro (G.D.); ⁴ Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania; ⁵ Faculty of Medicine, University of Medicine and Pharmacy “Carol Davila”, 06074 Bucharest, Romania; ⁶ Faculty of Medicine, Ovidius University of Constanta, 90057 Constanta, Romania; ⁷ Elena Ionescu@OVS.univ-ovidius.ro (E.V.I.); carmen.oprea@OVS.univ-ovidius.ro (C.O.); ⁸ irina.albadi@unimib.ro (I.A.); ⁹ Rubeval and Rehabilitation Seminars of Tighirlighi, 90610 Tighirlighi, Romania; ¹⁰ Teaching Emergency County Hospital “St. Apostol Andrei” Constanta, 90059 Constanta, Romania; * Correspondence: constantin.munteanu@unimib.ro (C.M.); gelu.onose@unimib.ro (G.O.)




Abstract: Abundant experimental data suggest that hydrogen sulfide (H₂S) is related to the pathophysiology of Diabetes Mellitus (DM). Multiple molecular mechanisms, including receptors, membrane ion channels, signaling molecules, enzymes, and transcription factors, are known to be responsible for the H₂S biological actions; however, H₂S is not fully documented as a gaseous signaling molecule interfering with DM and vascular-related pathology. In recent decades, multiple approaches regarding therapeutic exploitation of H₂S have been identified, either based on H₂S exogenous support or on its modulated endogenous biosynthesis. This paper aims to synthesize and systematize, as comprehensively as possible, the recent literature-related data regarding the therapeutic/rehabilitative role of H₂S in DM. This review was conducted following the “Preferred reporting items for systematic reviews and meta-analyses” (PRISMA) methodology, interrogating five international medically reviewed databases by specific keyword combinations “systematic” used consistently over the last five years (2017–2021). The respective search/filtered and selection methodology we applied has identified, in the first step, 212 articles. After deploying the next specific quest steps, 51 unique published papers qualified for minute analysis resulted. To these bibliographic resources obtained through the PRISMA methodology, in order to have the best available information coverage, we added 86 papers that were freely found by a direct internet search. Finally, we selected for a connected meta-analysis eight relevant reports that included 1237 human subjects enlisted from clinical trial registration platforms. Numerous H₂S-releasing/stimulating compounds have been produced, some being used in experimental models. However, very few of them were further advanced in clinical studies, indicating that the development of H₂S as a therapeutic agent is still at the beginning.

Keywords: hydrogen sulfide (H₂S); Diabetes Mellitus (DM); DM vascular-linked pathology; systematic review; oxidative phosphorylation; ROS (Reactive Oxygen Species)

1. Introduction
Diabetes Mellitus (DM) is a non-communicable chronic metabolic disease [1] characterized by prolonged hyperglycemia. Type 1 DM is a chronic condition in which the body's pancreatic β cells, destroyed by different causes, reduce insulin production. Instead, type


Int. J. Mol. Sci. 2022, 23, 6720; <https://doi.org/10.3390/ijms23126720> <https://www.mdpi.com/journal/ijms>



Protein aggregation is a defining feature of many neurodegenerative diseases. Amyloid-β, tau, α-synuclein, and TDP-43 accumulate when proteostasis mechanisms fail. Current evidence suggests that H₂S may influence protein folding, autophagy, and proteasomal activity, thereby contributing to the maintenance of protein homeostasis.

Pillar 5: Synaptic Plasticity

H₂S modulates NMDA receptors and supports learning, memory, and neuroplasticity



NEURO
CONCLAVE
2026
ADVANCING BRAIN HEALTH TOGETHER



International Journal of Molecular Sciences

MDPI

Review

Hydrogen Sulfide (H₂S- or H₂S_n-Polysulfides) in Synaptic Plasticity: Modulation of NMDA Receptors and Neurotransmitter Release in Learning and Memory

Constantin Munteanu ^{1,2,*}, Anca Irina Galaction ¹, Gelu Onose ^{2,3}, Marius Turnea ^{1,4} and Mariana Rotariu ¹

¹ Department of Biomedical Sciences, Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa", 700454 Iasi, Romania; anca.galaction@umfiasi.ro (A.I.G.); mariana.rotariu@umfiasi.ro (M.R.)

² Neuromuscular Rehabilitation Clinic Division, Clinical Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania; gelu.onose@umfiasi.ro

³ Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 030022 Bucharest, Romania

* Correspondence: constantin.munteanu.bio@umfiasi.ro (C.M.); marius.turnea@umfiasi.ro (M.T.)

Abstract: Hydrogen sulfide (H₂S) has emerged as a pivotal gaseous transmitter in the central nervous system, influencing synaptic plasticity, learning, and memory by modulating various molecular pathways. This review examines recent evidence regarding how H₂S regulates NMDA receptor function and neurotransmitter release in neuronal circuits. By synthesizing findings from animal and cellular models, we investigate the impacts of enzymatic H₂S production and exogenous H₂S on excitatory synaptic currents, long-term potentiation, and intracellular calcium signaling. Data suggest that H₂S interacts directly with NMDA receptor subunits, altering receptor function and modulating neuronal excitability. Simultaneously, H₂S promotes the release of neurotransmitters such as glutamate and GABA, shaping synaptic dynamics and plasticity. Furthermore, reports indicate that disruptions in H₂S metabolism contribute to cognitive impairments and neurodegenerative disorders, underscoring the potential therapeutic value of targeting H₂S-mediated pathways. Although the precise mechanisms of H₂S-induced changes in synaptic strength remain elusive, a growing body of evidence positions H₂S as a significant regulator of memory formation processes. This review calls for more rigorous exploration into the molecular underpinnings of H₂S in synaptic plasticity, paving the way for novel pharmacological interventions in cognitive dysfunction.


Keywords: hydrogen sulfide; NMDA receptor; synaptic plasticity; neurotransmitter release; cognitive function

check for updates

Academic Editors: Volkmar Lessmann and Manuela Dierker

Received: 9 February 2025
Revised: 21 March 2025
Accepted: 26 March 2025
Published: 28 March 2025

Citation: Munteanu, C.; Galaction, A.I.; Onose, G.; Turnea, M.; Rotariu, M. Hydrogen Sulfide (H₂S- or H₂S_n-Polysulfides) in Synaptic Plasticity: Modulation of NMDA Receptors and Neurotransmitter Release in Learning and Memory. *Int. J. Mol. Sci.* **2025**, *26*, 12345. [DOI: 10.3390/ijms260312345](#)




H₂S SUPPORTS SYNAPTIC PLASTICITY AND MAY IMPROVE COGNITIVE RESILIENCE.


H₂S is strongly linked to synaptic plasticity. Experimental studies demonstrate modulation of NMDA receptor activity, neurotransmitter release, calcium signaling, and long-term potentiation. These mechanisms place H₂S at the intersection between molecular signaling and higher-order functions such as learning, memory, and cognitive resilience.

ALZHEIMER'S DISEASE

THE H₂S-AD CASCADE





HOW REDUCED H₂S DRIVES THE ALZHEIMER'S CASCADE



H₂S DEFICIENCY INDUCES OXIDATIVE STRESS, PROMOTES AMYLOID/Tau PATHOLOGY, AND DRIVES NEURODEGENERATION IN **ALZHEIMER'S DISEASE**

Sources: Munteanu C. et al.
Mechanistic Intimate Insights into the Role of Hydrogen Sulfide in Alzheimer's Disease: A Recent Systematic Review.
International Journal of Molecular Sciences. 2023; 24(10): 8744.



Mechanistic Intimate Insights into the Role of Hydrogen Sulfide in Alzheimer's Disease: A Recent Systematic Review

Constantin Munteanu ^{1,2,*}, Mihail Hoteleu ², Cristina Popescu ^{2,3,4}, Ruxandra Postoiu ¹, Andrei Iordan ¹, Ilie Onu ¹ and Gelu Onose ^{2,3}

¹ Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa" Iasi, 700454, Iasi, Romania
² Teaching Emergency Hospital "Bagdasar-Arseni" (TEHBA), 041915 Bucharest, Romania
³ Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila" (UMPCD), 020022 Bucharest, Romania
⁴ Department of Individual Sports and Kinesotherapy, Faculty of Physical Education and Sport, Dunarea de Jos University of Galati, 80008 Galati, Romania
* Correspondence: constantin.munteanu@biomfiasi.ro (C.M.); cristina_popescu@recupere@yahoo.com (C.P.)

Abstract: In the rapidly evolving field of Alzheimer's Disease (AD) research, the intricate role of Hydrogen Sulfide (H₂S) has garnered critical attention for its diverse involvement in both pathological substrates and prospective therapeutic paradigms. While conventional pathophysiological models of AD have primarily emphasized the significance of amyloid-beta (Aβ) deposition and tau protein hyperphosphorylation, this targeted systematic review meticulously aggregates and rigorously appraises seminal contributions from the past year elucidating the complex mechanisms of H₂S in AD pathogenesis. Current scholarly literature accentuates H₂S's dual role, delineating its regulatory functions in critical cellular processes—such as neurotransmission, inflammation, and oxidative stress homeostasis—while concurrently highlighting its disruptive impact on quintessential AD biomarkers. Moreover, this review illuminates the nuanced mechanistic intimate interactions of H₂S in cerebrovascular and cardiovascular pathology associated with AD, thereby exploring avant-garde therapeutic modalities, including sulfurous mineral water inhalations and mud therapy. By emphasizing the potential for therapeutic modulation of H₂S via both donors and inhibitors, this review accentuates the imperative for future research endeavors to deepen our understanding, thereby potentially advancing novel diagnostic and therapeutic strategies in AD.

Keywords: Alzheimer's Disease; Hydrogen Sulfide (H₂S); Amyloid-beta (Aβ) Aggregation; Tau Hyperphosphorylation; Cellular Homeostasis; Neuroinflammation; Neuroprotection


Citation: To be added by editorial staff during production.

Academic Editor: Firstname Last-name

Received: date
Accepted: date
Published: date

1. Introduction

Alzheimer's Disease (AD), the predominant version of dementia, imposes a substantial public health burden [1], afflicting an estimated 50 million individuals globally [2].



In Alzheimer's disease, reduced H₂S bioavailability has been associated with oxidative stress, mitochondrial dysfunction, amyloid accumulation, and progressive cognitive decline. Although causality remains under investigation, multiple observations suggest that altered sulfur signaling may contribute to disease progression.

H₂S AND ALZHEIMER'S DISEASE: THE IMPORTANCE OF HOMEOSTASIS

H₂S IS BENEFICIAL ONLY WITHIN A PHYSIOLOGICAL RANGE – BOTH DEFICIENCY AND EXCESS CAN BE HARMFUL

TOO LITTLE H₂S

- Impaired signaling
- Increased oxidative stress
- Mitochondrial dysfunction
- Neuroinflammation
- Enhanced AD pathology



LOW
H₂S

OPTIMAL
H₂S
SIGNALING

HIGH
H₂S

TOO MUCH H₂S

- Oxidative/nitrosative stress
- Mitochondrial inhibition
- Protein sulfhydration excess
- Neuroinflammation
- Potential neurotoxicity




PHYSIOLOGICAL H₂S HOMEOSTASIS

Balanced redox state • Mitochondrial support • Controlled inflammation
Synaptic function • Neuronal survival

1 AMYLOID-β


Physiological H₂S may influence



May reduce Aβ aggregation
and support Aβ clearance

2 TAU

Physiological H₂S may modulate



May modulate tau phosphorylation
and reduce tau toxicity

3 MITOCHONDRIA

Physiological H₂S supports



Supports mitochondrial function,
but excessive H₂S may inhibit respiration
and impair bioenergetics

4 COGNITION

Physiological H₂S may be associated with



May support synaptic plasticity, learning
and memory – human evidence remains
limited and inconclusive



H₂S HOMEOSTASIS IS KEY:
NEITHER DEFICIENCY NOR EXCESS IS DESIRABLE.



Aβ pathology



Tau pathology



Mitochondrial
dysfunction



Synaptic
dysfunction



Cognitive
decline

MAINTAINING PHYSIOLOGICAL
H₂S LEVELS MAY HELP
PRESERVE NEURONAL
HEALTH IN ALZHEIMER'S DISEASE.

The Role of Hydrogen Sulfide (H₂S) in Epigenetic Regulation of Neurodegenerative Diseases: A Systematic Review

Bombonica Gabriela Dogaru ^{1,2} and Constantin Munteanu ^{3,4,*}

¹ Faculty of Medicine, "Tuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania

² Clinical Rehabilitation Hospital, 400437 Cluj-Napoca, Romania; dogarugabriela@gmail.com

³ Teaching Emergency Hospital "Bagdasar-Arseni" (TEHBA), 041913 Bucharest, Romania

⁴ Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa" Iași, 700454, Iași, Romania

* Correspondence: constantin.munteanu@umfiasi.ro

Abstract: This review explores the emerging role of hydrogen sulfide (H₂S) in modulating epigenetic mechanisms involved in neurodegenerative diseases. Accumulating evidence has begun to elucidate the multifaceted ways in which H₂S influences the epigenetic landscape and, subsequently, the progression of various neurodegenerative disorders, including Alzheimer's, Parkinson's, and Huntington's disease. H₂S can modulate key components of the epigenetic machinery, such as DNA methylation, histone modifications, and non-coding RNAs, impacting gene expression and cellular functions relevant to neuronal survival, inflammation, and synaptic plasticity. We synthesize recent research that positions H₂S as an essential player within this intricate network, with the potential to open new therapeutic avenues for these currently incurable conditions. Despite significant progress, there remains a considerable gap in our understanding of the precise molecular mechanisms and the potential therapeutic implications of modulating H₂S levels or its downstream targets. We conclude by identifying future directions for research aimed at exploiting the therapeutic potential of H₂S in neurodegenerative diseases.

Keywords: hydrogen sulfide; epigenetic regulation; neurodegenerative diseases; DNA methylation; Histone modifications; non-coding RNAs; Alzheimer's disease; Parkinson's disease; Huntington's disease

Cristian Dogaru, B.G., Munteanu, C. The Role of Hydrogen Sulfide (H₂S) in Epigenetic Regulation of Neurodegenerative Diseases: A Systematic Review. *Int. J. Mol. Sci.* **2024**, *25*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor(s) Name


Received: date

Revised: date

Accepted: date

1. Introduction


Neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's, pose a formidable challenge in modern medicine [1,2]. These conditions are characterized by the relentless and irreversible loss of neurons, leading to a gradual decline in cognitive and motor functions [3]. They have become a significant subset of non-communicable diseases, exacerbated by our longer human lifespan [4], impacting the lives of millions of individuals worldwide. Not only do these diseases cause emotional distress, but they also impose substantial economic burdens on society [5].



A key message is that H₂S biology follows a homeostatic model. Both deficiency and excess may be harmful. Physiological signaling appears to support mitochondrial function, synaptic activity, and redox balance, whereas disruption of this equilibrium may contribute to neurodegeneration. Therefore, the objective is not maximal H₂S exposure but optimal H₂S homeostasis.

PARKINSON'S DISEASE

LOSS OF DOPAMINERGIC NEURONS



PARKINSON'S DISEASE IS CHARACTERIZED BY THE PROGRESSIVE LOSS OF DOPAMINERGIC NEURONS IN THE SUBSTANTIA NIGRA

Parkinson's disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra. Oxidative stress, mitochondrial dysfunction, and neuroinflammation all participate in this process. These mechanisms overlap remarkably with the biological pathways regulated by H₂S.

nutrients **MDPI**

Review

Actual Data on Essential Trace Elements in Parkinson's Disease

Cristina Popescu ^{1,2}, Constantin Munteanu ^{2,3,4}, Aurea Spina ^{1,2}, Ioana Andone ^{1,2}, Roxana Bistriceanu ^{1,2}, Ruxandra Postoiu ^{1,2}, Andreea Suciu ^{1,2}, Sebastian Giuvara ^{1,2}, Andreea-Iulia Vladulescu-Trandafir ^{1,2}, Sorina Maria Aurelian ^{1,4}, Nadina Liana Pop ⁵, Vlad Ciobanu ⁶ and Gelu Onose ^{1,2}

¹ Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020221 Bucharest, Romania; cristina_popescu_nucupera@yahoo.com (C.P.); aurea_spina@yahoo.com (A.S.); ioanaandone1@yahoo.com (I.A.); roxana.bistriceanu@gmail.com (R.B.); postoiu.ruxandra@yahoo.com (R.P.); andreea_suciu@yahoo.com (A.S.); sebastian.giuvara@gmail.com (S.G.); andreea-iulia.trandafir@fcd.unifed.ro (A.-I.V.-T.); sorina.aurelian@unifed.ro (S.M.A.); vlad.ciobanu@fcd.unifed.ro (V.C.); ² Neurovascular Rehabilitation Clinic Division, Clinical Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania; ³ Department of Biomedical Sciences, Faculty of Medical Engineering, University of Medicine and Pharmacy "Gheorghe T. Popa" Iasi, 700491 Iasi, Romania; ⁴ Clinic of Geriatrics, Hospital of Chronic Diseases "St. Luca", 041915 Bucharest, Romania; ⁵ Department of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Clinicilor Street No. 1-3, 400009 Cluj-Napoca, Romania; popadina@yahoo.com; ⁶ Computer Science Department, Politehnica University of Bucharest, 060042 Bucharest, Romania; vlad.ciobanu@upb.ro

* Correspondence: constantin.munteanu.biolog@unifed.ro

Abstract: "Sola dosis facit venenum" (Paracelsus). Essential trace elements, crucial for maintaining neuronal function, have their dysregulation increasingly correlated with neurodegenerative disorders, particularly Parkinson's disease (PD). This systematic review aims to synthesize recent high-quality evidence regarding the involvement of essential trace elements, such as iron, zinc, copper, manganese, and selenium, in the pathogenesis and, consequently, as potential therapeutic targets of PD. A comprehensive literature search was conducted for articles published between 1 January 2023 and 31 December 2024. Out of an initial pool of 1231 identified studies, 63 met the methodological eligibility criteria according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. All potentially eligible interventional and observational studies were initially assessed using the Physiotherapy Evidence Database (PEDro) scale, which is commonly employed for evaluating the internal validity and statistical interpretability of clinical trials and rehabilitation-focused studies. Following the qualitative assessment using the PEDro scale, 18 studies were ultimately selected based on their scientific relevance and methodological rigor. To supplement the PEDro scoring, which is designed primarily for individual trials, we applied the AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews) checklist for the evaluation of the included systematic reviews or meta-analyses. The included studies employed a variety of clinical, postmortem, and experimental models to investigate trace-element concentrations and their mechanistic roles in PD. The findings revealed consistent patterns of iron accumulation in the substantia nigra, zinc's bidirectional effects on oxidative stress and autophagy, copper-induced α -synuclein aggregation, and the neuroprotective role of selenium via antioxidant pathways. Manganese was associated with mitochondrial dysfunction and neuroinflammation. Essential trace-element disturbances contribute to PD pathology through interconnected mechanisms involving redox imbalance, protein misfolding, and impaired cellular homeostasis. These elements may serve as both biomarkers and potential therapeutic tools, warranting further investigation into personalized metal-based interventions for PD.

Keywords: Parkinson's disease; substantia nigra; dopaminergic neurons; oxidative stress; neuroinflammation; essential trace elements; iron; zinc; copper; manganese; selenium; mitochondrial dysfunction; autophagy; protein misfolding; cellular homeostasis.

1. Introduction

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor symptoms such as tremor, rigidity, and bradykinesia. The pathogenesis of PD is complex, involving a combination of genetic and environmental factors. Recent research has highlighted the role of essential trace elements in the pathogenesis of PD, particularly in the context of oxidative stress, neuroinflammation, and mitochondrial dysfunction. This systematic review aims to synthesize recent high-quality evidence regarding the involvement of essential trace elements, such as iron, zinc, copper, manganese, and selenium, in the pathogenesis and, consequently, as potential therapeutic targets of PD. A comprehensive literature search was conducted for articles published between 1 January 2023 and 31 December 2024. Out of an initial pool of 1231 identified studies, 63 met the methodological eligibility criteria according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. All potentially eligible interventional and observational studies were initially assessed using the Physiotherapy Evidence Database (PEDro) scale, which is commonly employed for evaluating the internal validity and statistical interpretability of clinical trials and rehabilitation-focused studies. Following the qualitative assessment using the PEDro scale, 18 studies were ultimately selected based on their scientific relevance and methodological rigor. To supplement the PEDro scoring, which is designed primarily for individual trials, we applied the AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews) checklist for the evaluation of the included systematic reviews or meta-analyses. The included studies employed a variety of clinical, postmortem, and experimental models to investigate trace-element concentrations and their mechanistic roles in PD. The findings revealed consistent patterns of iron accumulation in the substantia nigra, zinc's bidirectional effects on oxidative stress and autophagy, copper-induced α -synuclein aggregation, and the neuroprotective role of selenium via antioxidant pathways. Manganese was associated with mitochondrial dysfunction and neuroinflammation. Essential trace-element disturbances contribute to PD pathology through interconnected mechanisms involving redox imbalance, protein misfolding, and impaired cellular homeostasis. These elements may serve as both biomarkers and potential therapeutic tools, warranting further investigation into personalized metal-based interventions for PD.

2. Methods

The search strategy was designed to identify relevant studies published between 1 January 2023 and 31 December 2024. The search was conducted in the following databases: PubMed, Scopus, and Web of Science. The search terms used were: "Parkinson's disease", "substantia nigra", "dopaminergic neurons", "oxidative stress", "neuroinflammation", "essential trace elements", "iron", "zinc", "copper", "manganese", "selenium", "mitochondrial dysfunction", "autophagy", "protein misfolding", "cellular homeostasis". The search results were screened based on the following criteria: (1) relevance to the topic, (2) methodological quality, and (3) availability of full-text. The search results were screened based on the following criteria: (1) relevance to the topic, (2) methodological quality, and (3) availability of full-text.

3. Results

The search results identified 1231 studies. After screening based on the criteria mentioned above, 63 studies were included in the review. The included studies employed a variety of clinical, postmortem, and experimental models to investigate trace-element concentrations and their mechanistic roles in PD. The findings revealed consistent patterns of iron accumulation in the substantia nigra, zinc's bidirectional effects on oxidative stress and autophagy, copper-induced α -synuclein aggregation, and the neuroprotective role of selenium via antioxidant pathways. Manganese was associated with mitochondrial dysfunction and neuroinflammation. Essential trace-element disturbances contribute to PD pathology through interconnected mechanisms involving redox imbalance, protein misfolding, and impaired cellular homeostasis. These elements may serve as both biomarkers and potential therapeutic tools, warranting further investigation into personalized metal-based interventions for PD.

4. Conclusions

The findings of this systematic review suggest that essential trace elements play a crucial role in the pathogenesis of PD. The dysregulation of these elements, particularly iron, zinc, copper, manganese, and selenium, is increasingly correlated with neurodegenerative disorders, particularly Parkinson's disease (PD). This systematic review aims to synthesize recent high-quality evidence regarding the involvement of essential trace elements, such as iron, zinc, copper, manganese, and selenium, in the pathogenesis and, consequently, as potential therapeutic targets of PD. A comprehensive literature search was conducted for articles published between 1 January 2023 and 31 December 2024. Out of an initial pool of 1231 identified studies, 63 met the methodological eligibility criteria according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. All potentially eligible interventional and observational studies were initially assessed using the Physiotherapy Evidence Database (PEDro) scale, which is commonly employed for evaluating the internal validity and statistical interpretability of clinical trials and rehabilitation-focused studies. Following the qualitative assessment using the PEDro scale, 18 studies were ultimately selected based on their scientific relevance and methodological rigor. To supplement the PEDro scoring, which is designed primarily for individual trials, we applied the AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews) checklist for the evaluation of the included systematic reviews or meta-analyses. The included studies employed a variety of clinical, postmortem, and experimental models to investigate trace-element concentrations and their mechanistic roles in PD. The findings revealed consistent patterns of iron accumulation in the substantia nigra, zinc's bidirectional effects on oxidative stress and autophagy, copper-induced α -synuclein aggregation, and the neuroprotective role of selenium via antioxidant pathways. Manganese was associated with mitochondrial dysfunction and neuroinflammation. Essential trace-element disturbances contribute to PD pathology through interconnected mechanisms involving redox imbalance, protein misfolding, and impaired cellular homeostasis. These elements may serve as both biomarkers and potential therapeutic tools, warranting further investigation into personalized metal-based interventions for PD.

5. Future Perspectives

Further research is needed to clarify the mechanistic roles of essential trace elements in PD. Future studies should focus on investigating the potential of trace-element supplementation as a therapeutic strategy for PD. Additionally, personalized medicine approaches that consider individual trace-element status may offer more targeted interventions for PD patients.

6. Acknowledgments

The authors would like to thank the following individuals for their contributions to this review: [Names of contributors]

7. Conflicts of Interest

The authors declare no conflict of interest.

8. References

1. [Reference 1]
2. [Reference 2]
3. [Reference 3]
4. [Reference 4]
5. [Reference 5]
6. [Reference 6]
7. [Reference 7]
8. [Reference 8]
9. [Reference 9]
10. [Reference 10]
11. [Reference 11]
12. [Reference 12]
13. [Reference 13]
14. [Reference 14]
15. [Reference 15]
16. [Reference 16]
17. [Reference 17]
18. [Reference 18]

9. Appendix

9.1. Table 1

Table 1: Summary of included studies.

9.2. Table 2

Table 2: Summary of included studies.

10. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

11. Data Availability Statement

Data Availability Statement: [Data availability statement]

12. Author Contributions

Author Contributions: [Author contributions]

13. Funding

Funding: [Funding information]

14. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

15. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

16. Ethics Statement

Ethics Statement: [Ethics statement]

17. Acknowledgments

Acknowledgments: [Acknowledgments]

18. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

19. References

References: [References]

20. Appendix

Appendix: [Appendix]

21. Table 1

Table 1: Summary of included studies.

22. Table 2

Table 2: Summary of included studies.

23. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

24. Data Availability Statement

Data Availability Statement: [Data availability statement]

25. Author Contributions

Author Contributions: [Author contributions]

26. Funding

Funding: [Funding information]

27. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

28. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

29. Ethics Statement

Ethics Statement: [Ethics statement]

30. Acknowledgments

Acknowledgments: [Acknowledgments]

31. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

32. References

References: [References]

33. Appendix

Appendix: [Appendix]

34. Table 1

Table 1: Summary of included studies.

35. Table 2

Table 2: Summary of included studies.

36. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

37. Data Availability Statement

Data Availability Statement: [Data availability statement]

38. Author Contributions

Author Contributions: [Author contributions]

39. Funding

Funding: [Funding information]

40. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

41. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

42. Ethics Statement

Ethics Statement: [Ethics statement]

43. Acknowledgments

Acknowledgments: [Acknowledgments]

44. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

45. References

References: [References]

46. Appendix

Appendix: [Appendix]

47. Table 1

Table 1: Summary of included studies.

48. Table 2

Table 2: Summary of included studies.

49. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

50. Data Availability Statement

Data Availability Statement: [Data availability statement]

51. Author Contributions

Author Contributions: [Author contributions]

52. Funding

Funding: [Funding information]

53. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

54. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

55. Ethics Statement

Ethics Statement: [Ethics statement]

56. Acknowledgments

Acknowledgments: [Acknowledgments]

57. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

58. References

References: [References]

59. Appendix

Appendix: [Appendix]

60. Table 1

Table 1: Summary of included studies.

61. Table 2

Table 2: Summary of included studies.

62. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

63. Data Availability Statement

Data Availability Statement: [Data availability statement]

64. Author Contributions

Author Contributions: [Author contributions]

65. Funding

Funding: [Funding information]

66. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

67. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

68. Ethics Statement

Ethics Statement: [Ethics statement]

69. Acknowledgments

Acknowledgments: [Acknowledgments]

70. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

71. References

References: [References]

72. Appendix

Appendix: [Appendix]

73. Table 1

Table 1: Summary of included studies.

74. Table 2

Table 2: Summary of included studies.

75. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

76. Data Availability Statement

Data Availability Statement: [Data availability statement]

77. Author Contributions

Author Contributions: [Author contributions]

78. Funding

Funding: [Funding information]

79. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

80. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

81. Ethics Statement

Ethics Statement: [Ethics statement]

82. Acknowledgments

Acknowledgments: [Acknowledgments]

83. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

84. References

References: [References]

85. Appendix

Appendix: [Appendix]

86. Table 1

Table 1: Summary of included studies.

87. Table 2

Table 2: Summary of included studies.

88. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

89. Data Availability Statement

Data Availability Statement: [Data availability statement]

90. Author Contributions

Author Contributions: [Author contributions]

91. Funding

Funding: [Funding information]

92. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

93. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

94. Ethics Statement

Ethics Statement: [Ethics statement]

95. Acknowledgments

Acknowledgments: [Acknowledgments]

96. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

97. References

References: [References]

98. Appendix

Appendix: [Appendix]

99. Table 1

Table 1: Summary of included studies.

100. Table 2

Table 2: Summary of included studies.

101. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

102. Data Availability Statement

Data Availability Statement: [Data availability statement]

103. Author Contributions

Author Contributions: [Author contributions]

104. Funding

Funding: [Funding information]

105. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

106. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

107. Ethics Statement

Ethics Statement: [Ethics statement]

108. Acknowledgments

Acknowledgments: [Acknowledgments]

109. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

110. References

References: [References]

111. Appendix

Appendix: [Appendix]

112. Table 1

Table 1: Summary of included studies.

113. Table 2

Table 2: Summary of included studies.

114. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

115. Data Availability Statement

Data Availability Statement: [Data availability statement]

116. Author Contributions

Author Contributions: [Author contributions]

117. Funding

Funding: [Funding information]

118. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

119. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

120. Ethics Statement

Ethics Statement: [Ethics statement]

121. Acknowledgments

Acknowledgments: [Acknowledgments]

122. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

123. References

References: [References]

124. Appendix

Appendix: [Appendix]

125. Table 1

Table 1: Summary of included studies.

126. Table 2

Table 2: Summary of included studies.

127. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

128. Data Availability Statement

Data Availability Statement: [Data availability statement]

129. Author Contributions

Author Contributions: [Author contributions]

130. Funding

Funding: [Funding information]

131. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

132. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

133. Ethics Statement

Ethics Statement: [Ethics statement]

134. Acknowledgments

Acknowledgments: [Acknowledgments]

135. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

136. References

References: [References]

137. Appendix

Appendix: [Appendix]

138. Table 1

Table 1: Summary of included studies.

139. Table 2

Table 2: Summary of included studies.

140. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

141. Data Availability Statement

Data Availability Statement: [Data availability statement]

142. Author Contributions

Author Contributions: [Author contributions]

143. Funding

Funding: [Funding information]

144. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

145. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

146. Ethics Statement

Ethics Statement: [Ethics statement]

147. Acknowledgments

Acknowledgments: [Acknowledgments]

148. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

149. References

References: [References]

150. Appendix

Appendix: [Appendix]

151. Table 1

Table 1: Summary of included studies.

152. Table 2

Table 2: Summary of included studies.

153. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

154. Data Availability Statement

Data Availability Statement: [Data availability statement]

155. Author Contributions

Author Contributions: [Author contributions]

156. Funding

Funding: [Funding information]

157. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

158. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

159. Ethics Statement

Ethics Statement: [Ethics statement]

160. Acknowledgments

Acknowledgments: [Acknowledgments]

161. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

162. References

References: [References]

163. Appendix

Appendix: [Appendix]

164. Table 1

Table 1: Summary of included studies.

165. Table 2

Table 2: Summary of included studies.

166. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

167. Data Availability Statement

Data Availability Statement: [Data availability statement]

168. Author Contributions

Author Contributions: [Author contributions]

169. Funding

Funding: [Funding information]

170. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

171. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

172. Ethics Statement

Ethics Statement: [Ethics statement]

173. Acknowledgments

Acknowledgments: [Acknowledgments]

174. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

175. References

References: [References]

176. Appendix

Appendix: [Appendix]

177. Table 1

Table 1: Summary of included studies.

178. Table 2

Table 2: Summary of included studies.

179. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

180. Data Availability Statement

Data Availability Statement: [Data availability statement]

181. Author Contributions

Author Contributions: [Author contributions]

182. Funding

Funding: [Funding information]

183. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

184. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

185. Ethics Statement

Ethics Statement: [Ethics statement]

186. Acknowledgments

Acknowledgments: [Acknowledgments]

187. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

188. References

References: [References]

189. Appendix

Appendix: [Appendix]

190. Table 1

Table 1: Summary of included studies.

191. Table 2

Table 2: Summary of included studies.

192. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

193. Data Availability Statement

Data Availability Statement: [Data availability statement]

194. Author Contributions

Author Contributions: [Author contributions]

195. Funding

Funding: [Funding information]

196. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

197. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

198. Ethics Statement

Ethics Statement: [Ethics statement]

199. Acknowledgments

Acknowledgments: [Acknowledgments]

200. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

201. References

References: [References]

202. Appendix

Appendix: [Appendix]

203. Table 1

Table 1: Summary of included studies.

204. Table 2

Table 2: Summary of included studies.

205. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

206. Data Availability Statement

Data Availability Statement: [Data availability statement]

207. Author Contributions

Author Contributions: [Author contributions]

208. Funding

Funding: [Funding information]

209. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

210. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

211. Ethics Statement

Ethics Statement: [Ethics statement]

212. Acknowledgments

Acknowledgments: [Acknowledgments]

213. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

214. References

References: [References]

215. Appendix

Appendix: [Appendix]

216. Table 1

Table 1: Summary of included studies.

217. Table 2

Table 2: Summary of included studies.

218. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

219. Data Availability Statement

Data Availability Statement: [Data availability statement]

220. Author Contributions

Author Contributions: [Author contributions]

221. Funding

Funding: [Funding information]

222. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

223. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

224. Ethics Statement

Ethics Statement: [Ethics statement]

225. Acknowledgments

Acknowledgments: [Acknowledgments]

226. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

227. References

References: [References]

228. Appendix

Appendix: [Appendix]

229. Table 1

Table 1: Summary of included studies.

230. Table 2

Table 2: Summary of included studies.

231. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

232. Data Availability Statement

Data Availability Statement: [Data availability statement]

233. Author Contributions

Author Contributions: [Author contributions]

234. Funding

Funding: [Funding information]

235. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

236. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

237. Ethics Statement

Ethics Statement: [Ethics statement]

238. Acknowledgments

Acknowledgments: [Acknowledgments]

239. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

240. References

References: [References]

241. Appendix

Appendix: [Appendix]

242. Table 1

Table 1: Summary of included studies.

243. Table 2

Table 2: Summary of included studies.

244. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

245. Data Availability Statement

Data Availability Statement: [Data availability statement]

246. Author Contributions

Author Contributions: [Author contributions]

247. Funding

Funding: [Funding information]

248. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

249. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

250. Ethics Statement

Ethics Statement: [Ethics statement]

251. Acknowledgments

Acknowledgments: [Acknowledgments]

252. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

253. References

References: [References]

254. Appendix

Appendix: [Appendix]

255. Table 1

Table 1: Summary of included studies.

256. Table 2

Table 2: Summary of included studies.

257. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

258. Data Availability Statement

Data Availability Statement: [Data availability statement]

259. Author Contributions

Author Contributions: [Author contributions]

260. Funding

Funding: [Funding information]

261. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

262. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

263. Ethics Statement

Ethics Statement: [Ethics statement]

264. Acknowledgments

Acknowledgments: [Acknowledgments]

265. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

266. References

References: [References]

267. Appendix

Appendix: [Appendix]

268. Table 1

Table 1: Summary of included studies.

269. Table 2

Table 2: Summary of included studies.

270. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

271. Data Availability Statement

Data Availability Statement: [Data availability statement]

272. Author Contributions

Author Contributions: [Author contributions]

273. Funding

Funding: [Funding information]

274. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

275. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

276. Ethics Statement

Ethics Statement: [Ethics statement]

277. Acknowledgments

Acknowledgments: [Acknowledgments]

278. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

279. References

References: [References]

280. Appendix

Appendix: [Appendix]

281. Table 1

Table 1: Summary of included studies.

282. Table 2

Table 2: Summary of included studies.

283. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

284. Data Availability Statement

Data Availability Statement: [Data availability statement]

285. Author Contributions

Author Contributions: [Author contributions]

286. Funding

Funding: [Funding information]

287. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

288. Informed Consent Statement

Informed Consent Statement: [Informed consent statement]

289. Ethics Statement

Ethics Statement: [Ethics statement]

290. Acknowledgments

Acknowledgments: [Acknowledgments]

291. Conflicts of Interest

Conflicts of Interest: [Conflicts of interest]

292. References

References: [References]

293. Appendix

Appendix: [Appendix]

294. Table 1

Table 1: Summary of included studies.

295. Table 2

Table 2: Summary of included studies.

296. Supplementary Materials

Supplementary Materials: [Links to supplementary materials]

297. Data Availability Statement

Data Availability Statement: [Data availability statement]

298. Author Contributions

Author Contributions: [Author contributions]

299. Funding

Funding: [Funding information]

300. Institutional Review Board Statement

Institutional Review Board Statement: [IRB statement]

301. Informed Consent Statement


In

H₂S AND DOPAMINERGIC PROTECTION

PHYSIOLOGICAL H₂S SIGNALING MAY MODULATE KEY PATHWAYS INVOLVED IN DOPAMINERGIC NEURON VULNERABILITY


OXIDATIVE STRESS

- ROS / RNS
- Redox imbalance
- Protein oxidation
- Lipid peroxidation



NEUROINFLAMMATION

- Microglial activation
- NF-κB activation
- ↑ Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- Chronic inflammation



PHYSIOLOGICAL
H₂S SIGNALING

DOPAMINERGIC NEURON

MITOCHONDRIAL DYSFUNCTION

- Complex I dysfunction
- ↓ ATP production
- Impaired bioenergetics
- Mitophagy imbalance



APOPTOSIS

- Mitochondrial (intrinsic) pathway activation
- Caspase activation
- DNA damage
- Cell death signaling



HOMEOSTASIS

TOO LITTLE H₂S
Impaired signaling
Higher vulnerability

TOO MUCH H₂S
Sulfide toxicity
Higher vulnerability

PHYSIOLOGICAL H₂S SIGNALING MAY INFLUENCE MULTIPLE MECHANISMS INVOLVED IN DOPAMINERGIC NEURON DEGENERATION.

CONCENTRATION
CONTEXT
DISEASE STAGE
MATTER

Review

Novelties on Neuroinflammation in Alzheimer's Disease—Focus on Gut and Oral Microbiota Involvement

Cristina Popescu ^{1,2,†}, Constantin Munteanu ^{2,3,*,†}, Aurelian Angheliescu ^{1,2}, Vlad Ciobanu ⁴, Aura Spinu ^{1,2}, Ioana Andone ^{1,2}, Mihaela Mandu ^{1,2}, Roxana Bistriceanu ^{1,2}, Mihai Băilă ^{1,2}, Ruxandra-Luciana Postoiu ^{1,2}, Andreea-Iulia Vlădulescu-Trandafir ^{1,2}, Sebastian Giuvra ^{1,2}, Alin-Daniel Malalea ^{1,2} and Gelu Onose ^{1,2}

¹ Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 02002 Bucharest, Romania; cristina_popescu@umfcd.ro (C.P.); aurelian.angheliescu@umfcd.ro (A.A.); aura.spinu@umfcd.ro (A.S.); ioana.andone@umfcd.ro (I.A.); roxana.bistriceanu@umfcd.ro (R.B.); mihai.baila@umfcd.ro (M.B.); ruxandra-luciana.postoiu@umfcd.ro (R.L.P.); andreea-iulia.vladulescu-trandafir@umfcd.ro (A.I.V.-T.); sebastian.giuvra@gmail.com (S.G.); alin.malalea@gmail.com (A.-D.M.); gelu.onose@umfcd.ro (G.O.)

² Neuromuscular Rehabilitation Clinic Division, Clinical Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania

³ Department of Biomedical Sciences, Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa" Iasi, 700454 Iasi, Romania

⁴ Department of Computer Science and Engineering, Faculty for Automatic Control and Computers, University Politehnica of Bucharest, 060042 Bucharest, Romania; vlad.ciobanu@upb.ro

* Correspondence: constantin.munteanu@umfiasi.ro (C.M.); mihaela.mandu@umfcd.ro (M.M.)
† These authors contributed equally to this work.



Citation: Popescu, C.; Munteanu, C.; Angheliescu, A.; Ciobanu, V.; Spinu, A.; Andone, I.; Mandu, M.; Bistriceanu, R.; Băilă, M.; Postoiu, R.-L.; et al. Novelties on Neuroinflammation in Alzheimer's Disease—Focus on Gut and Oral Microbiota Involvement. *Int. J. Mol. Sci.* **2024**, *25*, 11272. <https://doi.org/10.3390/ijms251011272>

Academic Editor: David Martin-Hernandez

Received: 23 September 2024


Revised: 5 October 2024

Accepted: 17 October 2024

Published: 19 October 2024

Abstract: Recent studies underscore the role of gut and oral microbiota in influencing neuroinflammation through the microbiota–gut–brain axis, including in Alzheimer's disease (AD). This review aims to provide a comprehensive synthesis of recent findings on the involvement of gut and oral microbiota in the neuroinflammatory processes associated with AD, emphasizing novel insights and therapeutic implications. This review reveals that dysbiosis in AD patients' gut and oral microbiota is linked to heightened peripheral and central inflammatory responses. Specific bacterial taxa, such as Bacteroides and Firmicutes in the gut, as well as Porphyromonas gingivalis in the oral cavity, are notably altered in AD, leading to significant changes in microglial activation and cytokine production. Gut microbiota alterations are associated with increased intestinal permeability, facilitating the translocation of endotoxins like lipopolysaccharides (LPS) into the bloodstream and exacerbating neuroinflammation by activating the brain's toll-like receptor 4 (TLR4) pathways. Furthermore, microbiota-derived metabolites, including short-chain fatty acids (SCFAs) and amyloid peptides, can cross the blood–brain barrier and modulate neuroinflammatory responses. While microbial amyloids may contribute to amyloid-beta aggregation in the brain, certain SCFAs like butyrate exhibit anti-inflammatory properties, suggesting a potential therapeutic avenue to mitigate neuroinflammation. This review not only highlights the critical role of microbiota in AD pathology but also offers a ray of hope by suggesting that modulating gut and oral microbiota could represent a novel therapeutic strategy for reducing neuroinflammation and slowing disease progression.

Keywords: Alzheimer's disease (AD); neuroinflammation; gut microbiota; dysbiosis; amyloid peptides



Rather than viewing H₂S as a cure, it is more accurate to view it as a modulator of neuronal vulnerability. Physiological H₂S signaling may influence oxidative stress, mitochondrial integrity, inflammatory responses, and apoptosis. Importantly, these effects are context-dependent and strongly influenced by concentration and disease stage.

GUT-BRAIN- H_2S AXIS

MICROBIOTA-DERIVED H_2S LINKS GUT FUNCTION AND BRAIN HEALTH

1. GUT MICROBIOTA

Diverse microbial communities in the healthy gut

2. MICROBIAL H_2S

Microbial production of hydrogen sulfide

H_2S

3. BRAIN

H_2S signaling reaches the brain and modulates multiple pathways

H_2S ACTIONS IN THE BRAIN



Neuroprotection

Reduces oxidative stress and neuronal injury



Anti-inflammatory

Modulates microglial activation and neuroinflammation



Redox balance

Restores redox homeostasis and antioxidant defenses



Mitochondrial support

Improves mitochondrial function and bioenergetics



Synaptic plasticity and cognition

Supports synaptic function, learning and memory



H_2S



The **gut microbiota** produces **H_2S** that reaches the **brain** and may influence multiple pathways involved in **neuroprotection** and **brain health**.



Citation: Munteanu, C.; Onose, G.; Rotariu, M.; Turnea, M.; Galaction, A.I. Role of Microbiota-Derived Hydrogen Sulfide (H_2S) in Modulating the Gut-Brain Axis: Implications for Alzheimer's and Parkinson's Disease Pathogenesis. *Biomedicines* 2024, 12, 2670. <https://doi.org/10.3390/biomed12022670>

Academic Editor: Marta Lualdi

Received: 27 October 2024
Revised: 11 November 2024
Accepted: 20 November 2024
Published: 23 November 2024




Abstract: Microbiota-derived hydrogen sulfide (H_2S) plays a crucial role in modulating the gut-brain axis, with significant implications for neurodegenerative diseases such as Alzheimer's and Parkinson's. H_2S is produced by sulfate-reducing bacteria in the gut and acts as a critical signaling molecule influencing brain health via various pathways, including regulating inflammation, oxidative stress, and immune responses. H_2S maintains gut barrier integrity at physiological levels and prevents systemic inflammation, which could impact neuroinflammation. However, as H_2S has a dual role or a Janus face, excessive H_2S production, often resulting from gut dysbiosis, can compromise the intestinal barrier and exacerbate neurodegenerative processes by promoting neuroinflammation and glial cell dysfunction. This imbalance is linked to the early pathogenesis of Alzheimer's and Parkinson's diseases, where the overproduction of H_2S exacerbates beta-amyloid deposition, tau hyperphosphorylation, and alpha-synuclein aggregation, driving neuroinflammatory responses and neuronal damage. Targeting gut microbiota to restore H_2S homeostasis through dietary interventions, probiotics, prebiotics, and fecal microbiota transplantation presents a promising therapeutic approach. By rebalancing the microbiota-derived H_2S , these strategies may mitigate neurodegeneration and offer novel treatments for Alzheimer's and Parkinson's diseases, underscoring the critical role of the gut-brain axis in maintaining central nervous system health.

Keywords: microbiota; dysbiosis; H_2S ; gut-brain axis; Alzheimer's disease; Parkinson's disease; glial cell dysfunction; neuroinflammation; neurodegeneration; probiotics; prebiotics


1. Introduction

The human gastrointestinal (GI) tract harbors a complex community of trillions of microorganisms, including bacteria, archaea, fungi, and viruses, collectively referred to as the gut microbiota [1]. These microorganisms are crucial for maintaining homeostasis and performing essential functions such as digestion, nutrient absorption, immune system regulation, and the maintenance of the intestinal barrier [2]. In recent years, a growing body of



The gut microbiota has emerged as a major source of biologically active sulfur metabolites. Microbial H_2S may influence systemic physiology and brain function through multiple signaling pathways. This gut-brain- H_2S axis represents one of the most rapidly expanding research areas in neurodegeneration.

EPIGENETIC REGULATION



H₂S may also influence epigenetic regulation. Current evidence suggests interactions with DNA methylation, histone modifications, and non-coding RNAs. These mechanisms provide a potential bridge between environmental exposures, microbiota-derived metabolites, and long-term regulation of neuronal gene expression.

International Journal of
Molecular Sciences

Review

The Role of Hydrogen Sulfide (H₂S) in Epigenetic Regulation of Neurodegenerative Diseases: A Systematic Review

Bombonica Gabriela Dogaru ^{1,2} and Constantin Munteanu ^{1,3,4,*}

¹ Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
² Clinical Rehabilitation Hospital, 400437 Cluj-Napoca, Romania; dogarugabriela@gmail.com
³ Teaching Emergency Hospital "Bagdasar-Arseni" (TEHBA), 041915 Bucharest, Romania
⁴ Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa" Iași, 700454, Iași, Romania
 * Correspondence: constantin.munteanu.biol@umfiasi.ro

Abstract: This review explores the emerging role of hydrogen sulfide (H₂S) in modulating epigenetic mechanisms involved in neurodegenerative diseases. Accumulating evidence has begun to elucidate the multifaceted ways in which H₂S influences the epigenetic landscape and, subsequently, the progression of various neurodegenerative disorders, including Alzheimer's, Parkinson's, and Huntington's disease. H₂S can modulate key components of the epigenetic machinery, such as DNA methylation, histone modifications, and non-coding RNAs, impacting gene expression and cellular functions relevant to neuronal survival, inflammation, and synaptic plasticity. We synthesize recent research that positions H₂S as an essential player within this intricate network, with the potential to open new therapeutic avenues for these currently incurable conditions. Despite significant progress, there remains a considerable gap in our understanding of the precise molecular mechanisms and the potential therapeutic implications of modulating H₂S levels or its downstream targets. We conclude by identifying future directions for research aimed at exploiting the therapeutic potential of H₂S in neurodegenerative diseases.

Keywords: hydrogen sulfide; epigenetic regulation; neurodegenerative diseases; DNA methylation; Histone modifications; non-coding RNAs; Alzheimer's disease; Parkinson's disease; Huntington's disease


Citation: Dogaru, B.G.; Munteanu, C. The Role of Hydrogen Sulfide (H₂S) in Epigenetic Regulation of Neurodegenerative Diseases: A Systematic Review. *Int. J. Mol. Sci.* **2023**, *24*, x. <https://doi.org/10.3390/xxxx>

Academic Editor(s) Name


Received: date
 Revised: date
 Accepted: date

1. Introduction

Neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's, pose a formidable challenge in modern medicine [1,2]. These conditions are characterized by the relentless and irreversible loss of neurons, leading to a gradual decline in cognitive and motor functions [3]. They have become a significant subset of non-communicable diseases, exacerbated by our longer human lifespan [4], impacting the lives of millions of individuals worldwide. Not only do these diseases cause emotional distress, but they also impose substantial economic burdens on society [5].



SULFHYDRATION (PERSULFIDATION)



pharmaceuticals

MDPI

Review

Harnessing Gasotransmitters to Combat Age-Related Oxidative Stress in Smooth Muscle and Endothelial Cells

Constantin Munteanu ^{1,2,*}, Anca Irina Galaction ^{1,3}, Gelu Onose ^{2,3}, Marius Turnea ^{1,4} and Mariana Rotariu ¹

¹ Department of Biomedical Sciences, Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa", 700454 Iasi, Romania; anca.galaction@umfiasi.ro (A.I.G.); mariana.rotariu@umfiasi.ro (M.R.)

² Neuromuscular Rehabilitation Clinic Division, Clinical Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania; gelu.onose@umfiasi.ro


³ Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania

⁴ Correspondence: constantin.munteanu@umfiasi.ro (C.M.); marius.turnea@umfiasi.ro (M.T.)

Abstract: Age-related oxidative stress is a critical factor in vascular dysfunction, contributing to hypertension and atherosclerosis. Smooth muscle cells and endothelial cells are particularly susceptible to oxidative damage, which exacerbates vascular aging through cellular senescence, chronic inflammation, and arterial stiffness. Gasotransmitters—hydrogen sulfide (H₂S), nitric oxide (NO), and carbon monoxide (CO)—are emerging as promising therapeutic agents for counteracting these processes. This review synthesizes findings from recent studies focusing on the mechanisms by which H₂S, NO, and CO influence vascular smooth muscle and endothelial cell function. Therapeutic strategies involving exogenous gasotransmitter delivery systems and combination therapies were analyzed. H₂S enhances mitochondrial bioenergetics, scavenges ROS, and activates antioxidant pathways. NO improves endothelial function, promotes vasodilation, and inhibits platelet aggregation. CO exhibits cytoprotective and anti-inflammatory effects by modulating heme oxygenase activity and ROS production. In preclinical studies, gasotransmitter-releasing molecules (e.g., NaHS, SNAP, CORMs) and targeted delivery systems show significant promise. Synergistic effects with lifestyle modifications and antioxidant therapies further enhance their therapeutic potential. In conclusion, gasotransmitters hold significant promise as therapeutic agents to combat age-related oxidative stress in vascular cells. Their multifaceted mechanisms and innovative delivery approaches make them potential candidates for treating vascular dysfunction and promoting healthy vascular aging. Further research is needed to translate these findings into clinical applications.

Keywords: gasotransmitters; oxidative stress; vascular aging; endothelial cells; smooth muscle cells; hydrogen sulfide; nitric oxide; carbon monoxide


1. Introduction



Perhaps the most distinctive mechanism of H₂S biology is sulfhydration, also known as persulfidation. This reversible post-translational modification converts protein thiols into persulfides, altering protein activity, transcription factor behavior, and cellular signaling. Increasingly, persulfidation is viewed as a fundamental mechanism of H₂S-mediated biological regulation.

THERAPEUTIC OPPORTUNITIES


THE FUTURE H₂S THERAPEUTIC ROADMAP



Several therapeutic strategies are currently being explored. These include H₂S-releasing compounds, nutritional interventions, microbiota modulation, and precision medicine approaches guided by biomarkers. While clinical translation remains at an early stage, the field is rapidly evolving.

H₂S-CENTERED MODEL OF NEURODEGENERATION

A SYSTEMS BIOLOGY NETWORK IN NEURODEGENERATION



System biology perspective: H₂S interacts with redox homeostasis, mitochondrial function, neuroinflammation, proteostasis, epigenetics, and the gut microbiota. These interactions are bidirectional and highly interconnected. H₂S therefore acts not as a single target, but as a network regulator.

KEY TAKE-HOME MESSAGES

1

H₂S IS A FUNDAMENTAL NEUROPROTECTIVE MOLECULE.

- Endogenous signaling molecule
- Essential for cellular homeostasis
- Protects neurons against multiple stresses
- Supports brain health and function



3

H₂S PRESERVES MITOCHONDRIAL FUNCTION.


- Supports ATP production
- Maintains mitochondrial dynamics
- Prevents mitochondrial damage
- Reduces apoptosis



5

H₂S IS A PROMISING THERAPEUTIC TARGET.

- Multi-target actions
- Broad neuroprotection
- Potential for many neurodegenerative diseases
- Basis for novel H₂S-based therapies



2


H₂S REGULATES REDOX HOMEOSTASIS.



- Enhances antioxidant defenses
- Scavenges reactive species
- Maintains redox balance
- Reduces oxidative and nitrosative stress

4

H₂S MODULATES NEUROINFLAMMATION.



- Inhibits microglial overactivation
- Reduces pro-inflammatory cytokines
- Promotes M2 (anti-inflammatory) phenotype
- Protects the blood-brain barrier



PROTECT
NEURONS



RESTORE
ENERGY



BALANCE
REDOX



CALM
INFLAMMATION



IMPROVE
OUTCOMES

H₂S: SMALL MOLECULE,
BIG IMPACT ON **BRAIN HEALTH**

H₂S is a fundamental signaling molecule with important neuroprotective functions. It contributes to redox balance, mitochondrial resilience, inflammatory regulation, and cellular homeostasis. Most importantly, H₂S biology teaches us that neuroprotection depends on maintaining balance rather than maximizing intervention."

Thank You!

HYDROGEN SULFIDE: FROM MOLECULE TO NEUROPROTECTION

REDOX BALANCE • MITOCHONDRIAL HEALTH • NEUROINFLAMMATION
PROTEOSTASIS • MICROBIOTA



Constantin Munteanu, PhD

Associate Professor, Biologist



E-mail: office@bioclima.ro
constantin.munteanu.biolog@umfiasi.ro



Website: www.bioclima.ro



Mobile: +4 0723 138 339

Small Molecule. Big Impact.
BETTER BRAIN HEALTH. BETTER LIFE.



REDOX
BALANCE



MITOCHONDRIAL
HEALTH



NEUROINFLAMMATION
CONTROL



PROTEOSTASIS
SUPPORT



MICROBIOTA
BALANCE